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Abstract: Cardiac autonomic neuropathy (CAN) is a common and often-underdiagnosed com-
plication of diabetes mellitus (DM). CAN is associated with increased mortality, cardiovascular 
disease, chronic kidney disease, and morbidity in patients with DM, but despite these significant 
consequences CAN often remains undiagnosed for a prolonged period. This is commonly due 
to the disease being asymptomatic until the later stages, as well as a lack of easily available 
screening strategies. In this article, we review the latest developments in the epidemiology, 
pathogenesis, diagnosis, consequences, and treatments of CAN in patients with DM.
Keywords: cardiovascular, autonomic, neuropathy, orthostatic hypotension, postural hypo-
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Introduction
Diabetes mellitus (DM) is a global health epidemic thought to be affecting 415 million 
people worldwide, with a further 318 million suffering with glucose intolerance and at 
increased risk of developing the disease.1 Cardiovascular disease (CVD) is the leading 
cause of mortality and morbidity in patients with DM, but diabetes-related micro-
vascular complications also have a significant impact on morbidity and mortality.2–4
Cardiac autonomic neuropathy (CAN) is a common underdiagnosed complication of 
DM.5,6 The impact of CAN on patients with DM can be devastating, with CAN shown 
to be associated with increased mortality, CVD, chronic kidney disease (CKD), and 
morbidity of DM.6–8 The aim of this manuscript is to review the latest developments 
related to the epidemiology, pathogenesis, diagnosis, consequences, and treatment of 
CAN in patients with DM.
Search strategies
A review of literature was conducted using PubMed, Google Scholar, and Medline. 
Several terms were used in combination, including “cardiac”, “ autonomic”, “neu-
ropathy”, “ dysfunction”, “cardiomyopathy”, “diabetes”, “treatment”, “diagnosis”, 
“definition”, “pathophysiology”, and “pathology”. These results were limited to studies 
published in the English language between 2012 and 2017, but references from within 
those texts were also used. In addition, we also consulted our previous review of this 
topic that was published in 2014.9
CAN epidemiology
Several studies examined the prevalence of CAN in patients with type 1 DM (T1DM) and 
type 2 DM (T2DM) (Table 1). These studies showed a large variation in CAN prevalence: 
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17%–66% in patients with T1DM and 31%–73% in patients 
with T2DM. This is thought to be due to discrepancies and 
variation in the criteria used to diagnose CAN, study popula-
tions, and variation in CAN risk factors, as shown in Table 1.9
CAN risk factors
CAN has several risk factors that are common to other 
diabetes- related vascular complications, such as glycemic 
control, diabetes duration, and CVD risk factors, among others.
Duration of diabetes
Diabetes duration is a major risk factor for the development of 
CAN in patients with T1DM and T2DM.6,14–16 The incidence of 
CAN has been reported to be 6% and 2% annually in patients 
with T1DM and T2DM, respectively.9 The prevalence of CAN 
increased from 9% at the close of the DCCT study to 31% 1 
year later.24 Similarly, the prevalence of CAN increased from 
19.8% in patients with prediabetes to 32.2% in patients newly 
diagnosed with T2DM,25 with higher prevalence reported in 
patients with T2DM and longer diabetes duration.14,26,27 The 
prevalence of CAN is often reported to be higher in T2DM 
compared to T1DM, despite the longer diabetes duration in 
patients with T1DM; this is likely a reflection of patients with 
T2DM often being older and more likely to have more CVD 
risk factors for CAN than patients with T1DM.
Glycemic control
Hyperglycemia plays an important role in the pathogenesis 
of diabetes-related microvascular complications,28 and hence 
it is not surprising that hyperglycemia has an unfavorable 
impact on the development and progression of CAN. DCCT 
showed a 50% decrease in CAN incidence over a 6.5-year 
follow-up in its intensive-therapy cohort.15 The benefits of 
intensive glycemic control during DCCT persisted for at 
least 14 years after the end of the study, despite glycated 
hemoglobin (HbA
1c
) differences between the intensive- and 
conventional-therapy arms disappearing after the end of 
randomization.29 Furthermore, participants in the DCCT 
intensive-therapy group who were free from CAN at the end 
of the study had a 31% reduction in risk of incident CAN 
when compared to those in the control arm (OR 0.69; 95% 
CI 0.51–0.93).15 However, those individuals diagnosed with 
CAN at the end of DCCT showed a higher risk of suffering 
CVD events in follow-up, which was not independent of pre-
vious glycemic exposure or the effect of metabolic memory.24
Cardiovascular risk factors
CVD risk factors, including obesity, smoking, hyperten-
sion, and hyperlipidemia, have all been associated with 
CAN development.14,30,31 In the EURODIAB prospective 
complications study, risk factors related to CAN develop-
ment were investigated over a 7.3-year follow-up in patients 
with T1DM. The study showed that systolic blood pressure 
(SBP; OR 1.1/10 mmHg, 95% CI 1–1.3), HbA
1c
 (OR 1.2 
per percentage point, 95% CI 1.1–1.4), and age (OR 1.3 
per decade, 95% CI 1.1–1.7) were associated with a higher 
risk of developing CAN.31 A cross-sectional study of 2,230 
participants with T2DM also showed that CAN patients had 
a higher prevalence of hypertension vs patients without CAN 
(57% vs 49%, P<0.001).32
One study suggested that central obesity was associated 
with CAN, alongside age, postprandial glycemia, and dia-
stolic blood pressure (DBP).25 Another study of 245 T1DM 
and 151 T2DM patients showed that CAN was independently 
associated with obesity (P=0.034) and that specifically in 
T2DM there was higher prevalence of CAN in obese patients 
(P=0.033).33 It may thus be suggested that weight loss might 
a have favorable impact on CAN.34
Microvascular complications
Microvascular complications share common mechanisms, 
and several studies have shown that microvascular com-
plications predict CAN development. For example, the 
EURODIAB study showed that the presence of retinopathy 
and albuminuria was associated with CAN.13 A large cohort 
study of 1,021 T2DM patients with CAN demonstrated that 
over a 7.5-year follow-up diabetic retinopathy (OR 1.513, 
95% CI 1.028–2.226; P=0.036) and higher levels of micro-
albuminuria (OR 1.515, 95% CI 1.031–2.228; P=0.035) 
predicted CAN progression.35 Similar results were found in 
a more recent study.36
Sex
The impact of sex on CAN epidemiology is controversial. 
The ACCORD trial, which included >8,000 patients with 
T2DM, showed higher CAN prevalence in women compared 
to men across all definitions of CAN used within the study.37 
A more recent study, though not statistically significant, 
also showed women had higher prevalence of CAN than 
men (65.2% vs 34.8%, P=0.059).38 However, other studies 
have shown no difference in CAN prevalence between men 
and women.13,32,39
Ethnicity
The impact of ethnicity on CAN prevalence has also been 
widely discussed in the literature, being cited as a possible 
risk factor for CAN, as lower rates of peripheral neuropathy 
(PN) were detected in South Asians when compared to white 
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Europeans with DM.40 This was further supported in a recent 
study that showed white Caucasians were twice as likely 
to have diabetic PN (DPN) as South Asians, although this 
did become nonsignificant when adiposity and height were 
adjusted for.23 However, unlike PN, CAN prevalence has not 
been shown to be different between ethnicities, despite these 
ethnic differences in PN prevalence.23 This suggests that 
despite similarities in the pathogenesis of PN and autonomic 
neuropathy (AN) in patients with DM, there remain specific 
mechanisms that might affect one and not the other that need 
to be further explored.
Pathogenesis of CAN
CAN pathogenesis is complex, multifactorial, and still under 
much debate. Many of the proposed mechanisms are centered 
on models of neuronal injury based on somatic neuropathy, 
rather than AN. There are similarities between somatic neu-
ropathy and AN, but there are also differences, as was shown 
by the STENO-2 trial,41 in which the most recent follow-up 
showed that multifactorial intervention (including intensive 
therapy or CVD risk factors) can prevent the progression of 
AN, while the effects on somatic neuropathy were limited.41
Hyperglycemia
Hyperglycemia can activate multiple pathways involved in 
the pathogenesis of CAN. Of these pathways, the majority 
are related to the metabolic and/or oxidative state of neuronal 
cells. Although these alone can cause excessive damage, 
when combined they result in mitochondrial dysfunction 
and formation of reactive oxygen species (ROS).42 Oxida-
tive stress can induce DNA damage, leading to activation of 
PARP and inhibition of GAPDH.43 This in turn can activate 
multiple pathways, including the polyol pathway, the hexos-
amine pathway, as well as activation of PKC and increased 
production of advanced glycation end products, which in turn 
correlate with the severity of autonomic nerve abnormalities 
in patients with DM.42,44–47
Recent studies have supported the theory that hypergly-
cemia also impairs neuronal regeneration, and suggested that 
an increase in plasma superoxide generation may be able to 
predict decline in cardiac nerve function, and in particular 
may be the main determinant in early cardiac autonomic 
dysfunction.48–50 In relation to CAN, increased ROS is thought 
to depress autonomic ganglion synaptic transmission, con-
tributing to increased risk of fatal cardiac arrhythmias, as 
well as to sudden death after myocardial infarction due to 
posttranslational protein modifications.51
Autoimmunity
CAN might occur as a result of autoimmune autonomic 
ganglionopathy. This is where autonomic failure occurs in 
the presence of antibodies to the nicotinic acetylcholine 
receptor of autonomic ganglia, leading to severe autonomic 
manifestations, eg, orthostatic intolerance, syncope, consti-
pation, gastroparesis, urinary retention, dry mouth, dry eyes, 
anhidrosis, and cognitive impairment.52,53 However, the role of 
autoimmunity in patients with diabetes and CAN remains con-
troversial.54–57 A recent small cross-sectional study did show 
that the presence of IgG antibodies was associated with AN 
(OR 9, 95% CI 1.3–61.03).58 However, there remains no clear 
consensus on the role of autoimmunity in CAN progression, 
and most studies showing a positive association have been 
in patients with T1DM. Therefore, whether autoimmunity 
contributes to CAN in patients with T2DM is still not clear.57,59
Genetics
Several genes have been linked to the development and pro-
gression of diabetic polyneuropathy and CAN, among which 
are TCF7L2, APOE, and ACE.60 Ciccacci et al showed an 
association between miRI146a and miR27a single-nucleotide 
polymorphisms and CAN susceptibility.61 However, a twin 
study by Osztovits et al found that genetic factors did not 
have a substantial influence on CV autonomic function, and 
the authors went on to say that environmental factors played 
a bigger role.62
Obstructive sleep apnea
Obstructive sleep apnea (OSA) is known to be common in 
patients with DM and believed to be associated with DPN in 
patients with T2DM.63,64 While obesity is a major risk factor 
for OSA, Janovsky et al showed that OSA was common in 
lean patients with T1DM and that OSA can be associated 
with CAN.65 Unpublished data from our group showed that 
OSA was associated with weaker sympathetic and parasym-
pathetic tone in patients with T2DM and that patients who 
were compliant with OSA treatment (continuous positive 
airway pressure) had improvements in several autonomic 
parameters over the follow-up period.66,67
The pathophysiology and relationship between OSA and 
CAN might differ between patients with T1DM and T2DM. 
The intermittent hypoxia that occurs with OSA could result 
in increased ROS and impaired microvascular function, 
leading to CAN.64 On the other hand, the relationship may 
be bidirectional, with CAN causing changes in respiratory 
drive and upper-airway tone, increasing the risk of OSA.
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Inflammation
Inflammation plays an important role in the pathogenesis of 
diabetes and its related micro- and macrovascular complica-
tions. CAN has been associated with increased inflammatory 
markers such as CRP, IL6, and TNFα, and adipose-tissue 
inflammation.47 However, the direction of the relationship 
between inflammation and CAN is not clear and could be 
bidirectional.47,68 Vinik et al suggested that the inflammatory 
response is controlled by a neural circuit in which the affer-
ent arc consists of nerves that sense injury and transmits the 
information via the vagus nerve to the brain stem, which in 
turn activates the cholinergic anti-inflammatory pathways 
modulating the response.47 Increased activity in the vagus 
nerve to the spleen reduces the innate immune system’s 
response to damage-associated molecular patterns and sup-
presses inflammation.47 Therefore, changes in vagal activity 
due to AN might have an impact on inflammatory responses.
Clinical manifestations and 
consequences of CAN
CAN only becomes symptomatic in the later stages of the disease 
as it advances (Figure 1).6,47 The denervation of both the auto-
nomic and peripheral nervous systems occurs in an ascending 
length-dependent manner.9,69,70 Therefore, the vagus nerve is usu-
ally the first nerve to be affect in CAN, resulting in patients pre-
senting with symptoms of sympathetic predominance. However, 
this is initially limited to baroreceptor abnormalities and changes 
in heart-rate variability (HRV), but as the disease progresses 
cardiac involvement becomes more evident and symptomatic.
Resting tachycardia
One of the earliest signs of CAN is asymptomatic abnor-
malities in heart rate (HR), which later progresses to resting 
tachycardia (90–130 bpm).47,71 A fixed and unresponsive HR 
to breathing is associated with complete cardiac denervation 
and severe CAN.47,72 Therefore, resting HR can be used as 
a diagnostic and prognostic tool in patients with DM after 
excluding other causes of tachycardia.9 Furthermore, a study 
of 11,400 T2DM patients concluded that resting tachycardia is 
associated with an increased risk of death and CV complica-
tions (HR 1.15/10, 95% CI 1.08–1.21; P<0.001). However, it 
was unclear whether this increased risk was a direct result of 
a higher resting HR or just a marker of other factors that may 
determine a poor outcome.73
Reduced exercise tolerance
Parasympathetic denervation and sympathetic predominance 
are known to impair exercise tolerance by reducing HR and 
blood pressure (BP) response to activity, as well as blunting the 
appropriate increases in cardiac output.47,71 Patients with CAN 
who are undertaking an exercise program should be warned 
that HR cannot be used as an indicator of exercise intensity.47,74
Orthostatic hypotension
Orthostatic hypotension is defined as a reduction in SBP 
>20 mmHg or DBP >10 mmHg following a postural change 
from supine to standing, and is deemed to be a late sign in 
CAN.71,74 In diabetes, it is thought to be the result of efferent 
sympathetic vasomotor denervation leading to a defective 
reflex arc, culminating in an inadequate HR response and 
peripheral vasodilation when a person stands.14,75 Symptoms 
can include faintness, dizziness, and light-headness, and in 
severe cases a syncopal episode.72 Several medications given 
to patients with diabetes can aggravate these symptoms, 
including diuretics, vasodilators, tricyclic antidepressants, 
and insulin.74,76
Figure 1 Stages of CAN.
Notes: CAN symptoms can include reduced exercise tolerance, silent ischemia, interoperative complications, and lower-limb complications. Adapted from Vinik AI, Erbas 
T, Casellini CM. Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. J Diabetes Investig. 2013;4(1):4–18. © 2013 Asian Association for the Study 
of Diabetes and Wiley Publishing Asia Pty Ltd.47
Abbreviations: CAN, cardiovascular autonomic neuropathy; HR, heart rate.
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QT prolongation
QT prolongation is associated with cardiac arrhythmias 
and sudden death.77 Its pathogenesis is multifactorial, but 
includes an imbalance in cardiac sympathetic innervation 
and left-ventricular hypertrophy, as is often seen in CAN.78
Silent ischemia and CVD
Silent coronary artery disease has been reported with varied 
prevalence (12%–34%) in patients with DM, and is dependent 
on age, diabetes duration, and the presence of other risk fac-
tors.79–82 In the DIAD study, CAN (based on Valsalva ratio) 
was strongly associated with silent myocardial ischemia 
independently of traditional CVD risk factors.47,81 CAN was 
also associated with a prolonged subjective angina threshold, 
meaning that electrocardiography changes occur prior to the 
onset of angina pectoris, and thus CAN patients may be more 
susceptible to silent myocardial ischemia and/or infarction.83
A study by Valensi et al showed that CAN was a better pre-
dictor of a major cardiac event than silent ischemia (P=0.04 
vs P<0.05), but that patients with CAN and associated silent 
ischemia had the highest risk.84 A meta-analysis of 12 cross-
sectional studies showed that CAN was associated with 
silent ischemia in patients with DM; the Mantel–Haenszel 
test estimated the prevalence risk ratio was 1.96 (95% CI 
1.53–2.51, P<0.001) for patients with CAN vs no CAN 
when CAN was defined using two or more measures.74 The 
pathophysiology linking these two conditions is still unclear, 
with several proposed mechanisms, including reduced pain 
threshold, changes to the myocardial autonomic pathways 
or ischemic processes, and a causative relationship with 
both conditions being the product of coronary artery disease 
present in diabetes.9
In the EURODIAB study, CAN was independently 
associated with CVD in patients with T1DM.31 Similarly, 
the DCCT and EDIC studies showed that CAN predicted 
long-term CVD events during follow-up.24 CAN was also 
found to be a predictor of cerebrovascular disease over 5–10 
years of follow-up in patients with T2DM.85–87
Cardiomyopathy
Diabetic cardiomyopathy results in systolic and diastolic 
dysfunction in the absence of structural and valvular cardiac 
disease, hypertension, or coronary vessel disease.88 The 
perceived mechanisms include left-ventricular hypertrophy, 
increased oxidative stress, altered substrate utilization, and 
mitochondrial dysfunction.89 The combination of sympathetic 
predominance and autonomic myocardial denervation leads 
to reduced coronary blood flow and thus diastolic and eventu-
ally systolic dysfunction.5,90
Peri- and intraoperative complications
Patients with CAN have a greater risk of anesthetic-related 
complications. Sufferers of CAN may have varied hemo-
dynamic response to induction and tracheal intubation, 
leading to intraoperative hypotension, which is thought to 
be due to an inability to vasoconstrict correctly after the use 
of vasodilatory agents, such as anesthesia.91,92 Furthermore, 
patients with CAN have been shown to have a two- to three-
fold increase in perioperative morbidity and mortality as a 
result of severe intraoperative hypothermia.91–93 It is thus 
vital that all patients with a diabetes diagnosis are subject to 
a thorough preoperative assessment to minimize any of these 
complications perioperatively.91
Lower-limb complications
Sudomotor dysfunction, which can lead to foot ulceration, is 
due to both PN and AN.9 A study over 5 years of 595 patients 
with T2DM showed that the development of foot ulcers was 
independently associated with CAN after adjustment for 
possible confounding factors (normal vs definite CAN, HR 
4.45, 95% CI 1.29–15.33).94 In addition, a study by Chahal 
et al suggested that there may be an association between sudo-
motor dysfunction and peripheral artery disease, which can 
contribute to foot ulceration and lower-limb amputations.95 
Autonomic dysfunction has been suggested to play an impor-
tant role in the pathogenesis of Charcot neuroarthropathy in 
addition to periphery sensory and motor neuropathy.9
Chronic kidney disease
A recent study of 755 patients showed that CAN was an 
independent predictor for developing CKD in patients with 
T2DM after a 9.6-year follow-up (HR 2.62, 95% CI 1.87–
3.67; P<0.001).96 CAN was also an independent predictor 
of estimated glomerular filtration-rate decline in patients 
with T2DM in another study.18 Similarly, in patients with 
T1DM, CAN predicted the development of albuminuria and 
estimated glomerular filtration-rate decline over a 14-year 
period.97
Anemia
Anemia is positively associated with CAN in patients with 
T2DM, despite adjustment for sex, age, smoking habits, 
body-mass index, ALT, hyperlipidemia, hypertension, DM 
duration, HbA
1c
, retinopathy, and nephropathy.32
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Mortality
Longitudinal studies have shown a 5-year mortality rate of 
16%–50% in both T1DM and T2DM once CAN had been 
diagnosed, with most of these attributed to sudden cardiac 
death.9,72 This large range was due to differences in study 
population and methodologies used to diagnose CAN. These 
include changes in the perception of myocardial ischemia, 
altered hemodynamic response to stress on the CV system 
(eg, surgery, infection, or anesthesia), QT-interval disper-
sion leading to cardiac arrhythmias, variations in autonomic 
cardiac innervation balance and focal regions of sympathetic 
denervation, and reinnervation of the myocardium.8
A meta-analysis of 15 studies including studies with a 
baseline assessment of HRV using one or more tests and 
follow-up mortality data showed that the pooled estimated 
relative mortality risk was 3.45 (95% CI 2.66–4.47, P<0.001) 
when CAN was defined as the presence of two or more abnor-
malities in cardiac autonomic function.9,98 The ACCORD trial 
also showed CAN to be an independent predictor of all-cause 
mortality (HR 2.14, 95% CI 1.37–3.37) and CVD mortality 
(HR 2.62, 95% CI 1.4–4.91) after a mean follow-up of 3.5 
years,37 while the EURODIAB IDDM complication study 
demonstrated that CAN had the strongest association with 
mortality when compared to other risk factors.99
Diagnosis and screening of CAN
Cardiac autonomic reflex tests
Cardiac autonomic reflex tests (CARTs) were first described 
by Ewing et al in 1980 (Table 2).71,100 The CAN Subcom-
mittee of the Toronto Consensus Panel defined CAN as the 
presence of at least two abnormal CARTs, presence of one 
abnormal CART as possible CAN, and presence of orthostatic 
hypotension with two or more abnormal CARTs as indicative 
of advanced CAN.6 CARTs are the gold standard in clinical 
Table 2 Summary of Ewing tests
CART What does it assess? Which branch of the 
autonomic nervous 
system does it 
measure?
Interpretation and 
definition
Cutoffs (age-
dependent)102
Diagnostic 
performance101
HR response to 
deep breathing 
(E:I ratio)103,111
Assesses beat-to-beat 
variation (R-R variation) 
during paced deep 
breathing
Tests for defects in 
parasympathetic activity 
by assessing ability of 
vagal nerve to slow HR
Gives an E:I ratio: longest 
R-R during expiration 
divided by shortest R-R 
during inspiration
1.22–1.1 (15–65 
years)
S1 = 19%
S2 = 98%
P=0.115
OR (95% CI) = 2.34 
(1.19–4.77)
HR response 
to standing 
(30:15 ratio)103,111
Assesses beat-to-beat 
variation (R-R variation) 
following standing
Tests for defects in 
parasympathetic activity 
by assessing ability of 
vagal nerve to slow HR
Gives the 30:15 ratio: 
R-R interval around 30th 
heartbeat divided by R-R 
interval around the 15th 
heartbeat
1.17–1.06 (15–65 
years)
S1 = 96%
S2 = 65%
P<0.001
OR (95% CI) = 44.07 
(12.68–153.25)
Valsalva maneuver 
(Valsalva ratio)104
Evaluates HR response 
during and after 
provoked increase in 
intrathoracic/abdominal 
pressure
Assesses both 
parasympathetic and 
sympathetic activity, but 
mainly parasympathetic
Gives Valsalva ratio: 
longest R-R interval 
in Phase IV divided by 
shortest R-R interval 
in Phase II and at very 
beginning of Phase III
1.23–1.16 (15–65 
years)
S1 = 62%
S2 = 92%
P=0.001
OR (95% CI) = 18.56 
(5.55–62.1)
BP response to 
standing (reduction in 
SBP)103,106,110
Assesses the 
baroreceptor reflex
Tests for defects in 
sympathetic activity 
by assessing ability to 
provide suitable HR and 
BP response to activity
Test result presented as 
difference in both SBP 
and DBP between sitting 
and standing
20 drop in SBP or 
10 drop in DBP
S1 = 51%
S2 = 71%
P=0.061
OR (95% CI) = 2.5 
(1.28–4.88)
BP response to 
sustained muscle 
contraction (rise in 
DBP)103,105
DBP increases caused 
by sustained muscle 
contraction with the 
use of a handgrip 
dynamometer
Tests for defects in 
sympathetic activity 
by assessing ability to 
provide suitable HR and 
BP response to activity
Test result presented 
as difference between 
highest DBP during 
examination and average 
DBP at rest
Should normally be 
>15 mmHg
S1 = 64%
S2 = 75%
P=0.002
OR (95% CI) = 5.22 
(2.6–10.55)
Notes: Phase I is a transient increase in BP and resulting bradycardia due to a mechanical rise in transthoracic pressure. Phase II is concomitant compensatory tachycardia 
due to reduced venous return and stroke volume leading to a decrease in BP. Phase III is a further transient reduction in BP and resulting tachycardia at the end of expiration 
due to pulmonary vasculature expansion. Phase IV is an abrupt rise in BP above baseline values with resulting bradycardia, thought to be the result of baroreceptor activation. 
Based on changes to hemodynamic parameters, various indices can be calculated, including the Valsalva ratio, which is derived from the longest R-R interval in Phase IV divided 
by the shortest R-R interval at the end of Phase II/beginning of Phase III.107 Normal values for cutoffs are age-dependent; some software manufacturers (such as Ansar) also 
provide their own normative values. S1 is sensitivity and S2 is specificity.
Abbreviations: HR, heart rate; CART, cardiac autonomic reflex test; E:I, expiration:inspiration; SBP, systolic blood pressure; DBP, diastolic blood pressure.
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2017:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
428
Fisher and Tahrani
autonomic testing, as they are all noninvasive, safe, and well 
standardized.21,100 While CARTs are measures of CAN, they 
are also measures of cardiac function, which can be affected 
in patients with CAN.
Pafili et al compared the results from each individual 
CART and their combination against Ewing’s battery of 
tests. The study included 152 patients with a median diabetes 
duration of 12 years and mean age of 64.51±7.85 years. It 
was concluded that the 30:15 ratio demonstrated the best 
diagnostic indicator for CAN, with 96% sensitivity, 65% 
specificity, 94% negative predictive value, and OR of 21.14. It 
also suggested that if a 30:15 ratio indicated CAN, diagnostic 
accuracy could be increased if combined with the Valsalva 
ratio, a rise in DBP, and/or E:I ratio.101
In a study in a rural area of south India, 126 patients 
with T2DM were compared with 152 age- and sex-matched 
healthy controls. CAN prevalence was 53.2% in patients 
with T2DM, and HRV to deep breathing and DBP response 
to isometric exercise were the most sensitive tests for detect-
ing parasympathetic and sympathetic AN when compared 
to all other Ewing CARTs.108 Abnormal values in Valsalva 
ratio, HRV to deep breathing, and immediate HR response 
to standing were used to diagnose parasympathetic dysfunc-
tion, and abnormal values in BP response to standing and 
BP response to isometric exercise were used to diagnose 
sympathetic dysfunction.108 Another study that evaluated 
patients with T1DM vs age- and sex-matched healthy controls 
demonstrated that HRV parameters and HR recovery were 
significantly reduced in T1DM patients when compared to 
their healthy counterparts and that HRV parameters also 
correlated with HR recovery.109
Spectral analysis of heart-rate variability
As previously discussed, CAN often remains subclinical 
before clinical manifestations are present. Subclinical CAN 
can be detected through a reduction in HRV.21 In healthy 
individuals, there is normal beat-to-beat variation during 
inspiration and expiration, which is driven by sympathetic 
and parasympathetic activity.9,110 Therefore, abnormal beat-
to-beat variations may be indicative of early changes to 
myocardial autonomic innervation. HRV may be assessed 
by time-domain analysis or frequency-domain analysis, with 
the former looking at statistical analysis of R-R intervals 
(SD of all normal R-R intervals and root-mean square of 
the difference of successive R-R intervals) and the latter at 
spectral analysis.21 Studies have shown that HRV abnormali-
ties can be present at the time of diagnosis and that time- and 
frequency-domain analysis may permit more accurate evalu-
ation of CV parasympathetic and sympathetic activity.21,76 
Power spectral analysis of HRV can be carried out under 
resting conditions with demonstration of low-frequency 
(LF; 0.04–0.15 Hz) and high-frequency (HF; 0.15–0.4 Hz) 
components. The LF component of the power spectrum of 
HRV primarily reflects sympathetic activity, whereas the 
HF component (also termed the respiratory frequency [RF]) 
primarily reflects parasympathetic activity. LF:RF ratios are 
calculated, and provide a measure of sympathetic/parasym-
pathetic activity (Figure 2).3
Scintigraphy
Scintigraphy allows the quantitative evaluation of sympathetic 
cardiac innervation through the use of single-photon-emis-
sion computed tomography ± positron-emission tomogra-
phy and sympathetic neurotransmitter analogues, such as 
123I-metaiodobenylguanide and 11C-metahydroxyephedrine, 
respectively.9,76 However, these tests are specialized and 
expensive, and hence most of their use is limited to research 
studies, rather than routine clinical care.
Baroreflex sensitivity
An increase in BP is normally detected by baroreceptors, 
inducing a reflective increase in vagal activity and reduction 
in sympathetic activity.9 This results in a reduction in car-
diac output, as well as peripheral vasodilation to control the 
increase in BP.9 The opposite occurs when there is a reduction 
in BP, and thus baroreflex sensitivity (BRS) can assess both 
sympathetic and parasympathetic activities.9
BRS can be examined using pharmacological methods 
(such as intravenous bolus injection of epinephrine) or non-
pharmacological techniques (physical maneuvers, such as 
postural change).9 The former is considered the gold standard 
to date for evaluating BRS. Both techniques require a con-
tinuous measure of BP and a continuous and synchronized 
measure of HR (R-R interval).9 Furthermore, BRS can be 
estimated spontaneously through the observation of fluctua-
tions of BP and R-R intervals.111
The use of BRS as a method of CAN diagnosis has also 
been looked at in comparison to healthy controls. Kamińska 
et al found that BRS was significantly lower in T1DM 
patients with CAN than those without CAN and that BRS 
did not  differ significantly between those without CAN 
and the sex- and age-matched control group.112 This was 
further supported by a study showing that T1DM patients 
had decreased mean BRS in both ms/mmHg and mHz/
mmHg when compared to age-matched controls (P=0.05 
and P=0.17, respectively).113
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Corneal confocal microscopy
Corneal confocal microscopy (CCM) is an ophthalmic 
imaging technique that can accurately determine damage to 
corneal nerve fibers in patients with diabetes. These fibers 
have been shown to have a similar structure to type Aδ and 
small autonomic C fibers, and thus CCM may be able to 
detect CAN.114 Tavakoli et al found that CCM may be used 
to diagnose subclinical and overt diabetic AN (DAN; based 
on the composite autonomic scoring scale).115 There were 
progressive and significant reductions in nerve-fiber density, 
nerve-branch density, and nerve-fiber length in patients 
with DAN vs healthy control and patients without DAN. 
Another study showed that CCM could represent a new and 
noninvasive tool in the diagnosis of CAN in T1DM, as cor-
neal nerve-fiber density was lower in patients with CAN vs 
without CAN (based on HRV and postural hypotension).116 
This is still an evolving area of research, but could present a 
new noninvasive method for CAN screening and diagnosis 
in the future.
Screening
The Toronto Consensus Panel recommended screening 
for CAN, as it can be used as a risk-stratification tool for 
diabetes-related complications and CV mortality and morbid-
ity.6 The American Diabetes Association also recommended 
screening for CAN at the time of diagnosis for T2DM and 
within 5 years of diagnosis for T1DM, particularly if other 
complications are present.117 CAN screening should also be 
considered in patients with DM who are undergoing elective 
surgery, as well as those patients who have suffered from 
cardiac events, including following myocardial infarction, 
as CAN predicted adverse outcomes.3,29
Treatment of CAN
Early determination of CAN is vital to the success of thera-
peutic input, as it has been suggested that CV denervation 
may be reversible if diagnosed soon after onset.118 The aim of 
CAN treatment is symptom control or slowing progression. 
Current methods use a combination of nonpharmacological 
and pharmacological approaches, including lifestyle modi-
fication, intensive glycemic control, and treating underlying 
risk factors, such as hyperlipidemia and hypertension.
Despite similarities in the pathogenesis of CAN and DPN, 
they are not the same disease. The STENO-2 trial showed 
improvements in CAN, but not DPN.41 In addition, CAN and 
DPN do not always coexist, despite similar pathogenesis, sug-
gesting that these two conditions are not the same. It has also 
been shown that the ethnic differences seen in DPN prevalence 
between South Asians and white Caucasians are not seen 
in CAN. This could contribute to the differences observed 
between CAN and DPN responses to treatment. However, 
when considering treatment, it is important to consider the 
Figure 2 Spectral analysis of HRV.
Note: Reproduced from Vinik AI, Erbas T, Casellini CM. Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. J Diabetes Investig. 2013;4(1):4–18. 
© 2013 Asian Association for the Study of Diabetes and Wiley Publishing Asia Pty Ltd.47
Abbreviations: HRV, heart-rate variability; PS, parasympathetic; S, sympathetic ; sdNN, standard deviations of all normal beat-to-beat intervals.
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treatment modality and how responses were measured. For 
example, an improvement in the gold standard for DPN – 
nerve-conduction studies – does not necessarily correlate with 
an improvement in CAN and vice versa, whereas if CCM, 
discussed earlier, were used as a measure of DPN, it may lead 
to a different result. Indeed, following islet-cell transplant, 
CCM shows improvements in corneal nerves.115,116
Lifestyle modifications
Increased physical activity has been demonstrated to improve 
HRV and lower resting HR.119 Even simple activity, such as 
dog walking, could improve parasympathetic activity.120 The 
Diabetes Prevention Program demonstrated that lifestyle 
modifications were superior to metformin or placebo in 
regard to improvement in autonomic dysfunction (assessed 
with HRV and QT indices).121 A review by Voulgari et al 
concluded that moderate endurance and aerobic exercise 
improved HRV and parasympathetic dominance in patients 
with T1DM or T2DM.122 Esposito et al suggested that 
improvement in autonomic function following physical 
activity may be related to improvements in tissue hypoxia.123
Intensive glycemic control
The DCCT trial showed that intensive glycemic control 
reduced CAN incidence by 50% in T1DM over a 6.5-year 
follow-up when compared to conventional therapy (7% vs 
14%, P<0.004).15,29,124 These beneficial effects of intensive 
glycemic control in DCCT persisted during long-term follow-
up in the EDIC study,15 and thus early intervention with 
intensive therapy in patients with T1DM may help reduce 
the progression and development of CAN. Additionally, 
the SEARCH CVD study looked at subclinical autonomic 
dysfunction in 354 young T1DM patients. Dysfunction was 
assessed with HRV testing and the presence of parasympa-
thetic loss with sympathetic override, and HbA
1c
 >7.5% was 
independently associated with the presence of subclinical 
CAN when compared to a control group without DM.125
The effects of intensive glycemic control on CAN in 
patients with T2DM is still unclear.5 The Veterans Affairs 
Cooperative Study suggested no impact of intensive glyce-
mic control on CAN.126 In another randomized controlled 
trial (RCT), intensive glycemic control in newly diagnosed 
T2DM in primary care did not have an impact on CAN preva-
lence at 6-year follow-up.39 Conversely, the STENO-2 trial 
demonstrated that intensive multifactorial treatment (includ-
ing behavior modification and intensive therapy targeting 
hyperglycemia and CVD risk factors) lowered progression 
to AN (based on HRV during paced breathing and orthostatic 
hypotension) in T2DM (OR 0.32, 95% CI 0.12–0.78);127 these 
benefits were sustained at the 2-year follow-up.41
Pathogenesis-based pharmacotherapy
As discussed in the pathogenesis of CAN, hyperglycemia 
results in the production of excessive ROS, resulting in 
endothelial dysfunction and neuronal disease.34 Therefore, 
several antioxidants have been suggested as treatment for 
CAN. Small studies using α-lipoic acid and vitamin E 
suggested that these agents might have a favorable impact 
on CAN.6,34,128,129 However, a more recent RCT that used a 
triple-antioxidant regime (allopurinol, α-lipoic acid, and 
nicotinamide) over the course of 2 years failed to prevent 
progression of CAN and had no effect on myocardial perfu-
sion, as demonstrated with scintigraphic imaging modali-
ties.130 The effects of α-lipoic acid in the DEKAN RCT were 
only modest and only seen at 4 months.128 A small RCT in 
patients with T1DM also showed that C-peptide treatment 
might improve CAN over a 6-month period.131
Aldose reductase inhibitors, which block the polyol path-
way, have been shown to improve autonomic function in three 
or more of the standardized CARTs, but were ineffective in 
advanced CAN.132 Another study found that aldose reductase 
inhibitors stabilized or partially reversed left-ventricular 
abnormalities in patients with CAN.133 ACE inhibitors, par-
ticularly quinapril, have also been shown to improve parasym-
pathetic/sympathetic imbalance.30,133,134 ACE inhibitors may 
also be combined with α-lipoic acid to increase HRV, as dem-
onstrated by Ziegler et al.135 Cardioselective β-blockers can 
have a positive effect on autonomic dysfunction.136 Ebbehøj 
et al found that metoprolol improved autonomic function in 
patients with T1DM when used in combination with an ACE 
inhibitor.137 In the Beta-Blocker Heart Attack trial, propranolol 
was given to patients with DM following myocardial infarc-
tion, and was shown to improve parasympathetic tone and 
decrease morning sympathetic predominance.138
Treatment of orthostatic hypotension
Management of orthostatic hypotension in CAN is complex, 
and the condition is difficult to treat.5 Nonpharmacological 
interventions include increasing water consumption, avoid-
ing sudden changes in body posture, reducing physical 
maneuvers that increase intra-abdominal and intrathoracic 
pressure, use of stockings of the lower extremities, and 
eating smaller and more frequent meals.5,80 Additionally, 
certain  medications have been associated with orthostatic 
hypotension and should thus be stopped in patients who are 
symptomatic, including tricyclic antidepressants, diuret-
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ics, and α-adrenoreceptor antagonists.5,9 If these methods 
are unsuccessful, then pharmacological methods should be 
considered on a risk–benefit basis: weighing up an increase 
in standing BP against prevention of supine hypotension.9,80
Midodrine is a peripheral selective α
1
-adrenergic agonist 
that causes peripheral vasoconstriction of arterioles and veins 
and is the only Food and Drug Administration-approved drug, 
hence its common use.9 Other pharmacological agents used 
in the treatment of orthostatic hypotension include fludro-
cortisone, which is a synthetic mineralocorticoid, octreotide, 
which inhibits the release of vasoactive peptides in the gas-
trointestinal tract, leading to an increase in splanchnic vaso-
constriction and a rise in mean arterial BP, erythropoietin, 
which increases intravascular volume and blood viscosity, 
and pyridostigmine, which is a cholinesterase inhibitor.139
Conclusion
CAN is very common and often undiagnosed in patients 
with DM. Intensive multifactorial intervention targeting 
lifestyle, glycemic control, and CVD risk factors prevents 
the development and slows the progression of CAN. 
Identifying patients with CAN is important, as CAN is 
associated with increased mortality, CVD, CKD, periop-
erative morbidity, and lower-limb complications. As such, 
these patients should receive appropriate follow up and 
preventive treatments to prevent or slow the progression 
of these complications. CAN should be diagnosed as per 
the Toronto Consensus Panel statement using standardized 
CARTs. Further research into the pathogenesis of CAN is 
important, in order to identify novel treatment targets and 
develop new therapies.
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